Oncology Therapeutics

About Glycan Therapeutics

Glycan Therapeutics is a private, pre-clinical stage biotech pioneering a new class of medicines based on glycobiology. The company's core technology platform enables the rational design of glycan-targeting molecules, including antibodies and vaccines, to modulate immune responses and disrupt disease mechanisms. Its initial pipeline focuses on oncology and infectious diseases, seeking to address limitations of current therapies. As a platform company, it operates a pre-revenue business model typical of early-stage biotechs, relying on venture funding and potential partnerships for advancement.

About PAI Life Sciences

PAI Life Sciences is a private, clinical-stage biotech with a dual mission: serving as a key supplier of research adjuvants and developing a proprietary pipeline targeting neglected tropical diseases (NTDs). Its core strategy is 'Serving the Underserved,' addressing diseases overlooked by larger pharmaceutical companies. The company has advanced its lead schistosomiasis vaccine candidate into human clinical trials (Phase 1 initiated in May 2022) and maintains a broader pipeline including programs for lymphatic filariasis, tuberculosis, and onchocerciasis. While currently pre-revenue from its therapeutic pipeline, it generates early revenue through its adjuvant supply business.

Therapeutic Areas

Other Cancer Drugs